Stockscreener 앱 받기
0.0001
99.40%
-0.0167
Vaxxinity Inc 주식(VAXX)의 최신 뉴스
Vaxxinity (VAXX) Stock Trends and Sentiment 2026 - MarketBeat
Vaxxinity, Inc. Revenue Breakdown – OTC:VAXX - TradingView
If You Invested $1,000 in Vaxxinity, Inc. (VAXX) - Stock Titan
Price to sales forward of Vaxxinity, Inc. – OTC:VAXX - TradingView
Vaxxinity (VAXX) Insider Trading Activity 2026 - MarketBeat
Vaxxinity Inc Class A Actuals & Estimates (OTC:VAXX) - TradingView
Number of shareholders of Vaxxinity, Inc. – OTC:VAXX - TradingView
Vaxxinity Inc stock (US92239B1035): focus on vaccine pipeline after recent financing update - AD HOC NEWS
Vaxxinity Inc stock (US92239B1035): Trading at historic low amid biotech challenges - AD HOC NEWS
VAXX Stock Crashes 99.5% on NASDAQ: Vaxxinity Inc. Hits Record Low - Meyka
MAHA ACTION WELCOMES BIOTECH PIONEER LOU REESE TO ITS BOARD OF DIRECTORS - Yahoo Finance
Why Is Vaxxinity, Inc. (VAXX) Stock Down Today? - Meyka
Vaxxinity, Inc.Class A Common Stock (Nasdaq:VAXX) Stock Quote - The Chronicle-Journal
Vaxxinity Inc Stock: Pioneering Synthetic Vaccines in a Competitive Biotech Landscape for North Amer - AD HOC NEWS
VAXX (Vaxxinity) NASDAQ $0.0001 pre-market 27 Mar 2026: Top loser, clinical risk - Meyka
Vaxxinity Inc stock faces Nasdaq delisting risk amid biotech funding crunch - ad-hoc-news.de
VAXX (Vaxxinity, NASDAQ) at $0.0075 on 19 Mar 2026: Earnings could change momentum - Meyka
Vaxxinity Inc Stock (ISIN: US92239B1035) Faces Uncertainty Amid Biotech Sector Headwinds - AD HOC NEWS
Critical Review: iBio (NYSE:IBIO) versus Vaxxinity (NASDAQ:VAXX) - Defense World
VAXX stock at $0.0001 intraday on 11 Feb 2026: critical risks for NASDAQ holders - Meyka
VAXX Vaxxinity, Inc. drops 99% to $0.0001 on NASDAQ 19 Jan 2026: outlook - Meyka
Dallas District Court Split in High-Stakes Stock Dispute - Inforney News
Top 6 Healthcare Stock Picks in 2025 - timothysykes.com
VAXX Stock Price, News & Analysis - Stock Titan
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows - Pharmaceutical Technology
How a new kind of vaccine could lead to the eradication of Alzheimer's and dementia - New Scientist
Vaxxinity, Inc. (VAXX) stock historical prices and data - Yahoo Finance Australia
Vaxxinity - The Pharma Letter
A Potential Parkinson’s Treatment Has Promising Results - Time Magazine
Parkinson's Prevention May Include Tetanus Vaccination - Walgreens
Vaxxinity’s Immunotherapy Meets Phase I Goals in Parkinson’s Patients - Inside Precision Medicine
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial - Nature
AZTR Stock Price and Chart — AMEX:AZTR - TradingView
Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market - Fierce Biotech
VAXX Stock Price and Chart — OTC:VAXX - TradingView
Vaxxinity Inc Cl A (VAXX) Stock Price and News - The Globe and Mail
Vaxxinity, Inc. Financial Statements – OTC:VAXX - TradingView
Why Is Vaxxinity (VAXX) Stock Up 39% Today? - InvestorPlace
5/3/24 jj’s Watchlist. 🚨🚨🚨 - Moomoo
Why Is Vaxxinity (VAXX) Stock Down 58% Today? - TradingView
Vaxxinity Issues Shareholder Letter - Yahoo Finance
Vaxxinity | 10-K: FY2023 Annual Report - Moomoo
Parkinson's Drug Reduces Disease Markers in Breakthrough Trial - ScienceAlert
AD/PD 2024: Vaxxinity reveals Phase I success with Parkinson’s vaccine - Pharmaceutical Technology
Vaxxinity reports breakthrough in Parkinson's treatment By Investing.com - Investing.com UK
Peek inside the Space Coast vaccine lab working to create humanity’s moonshot - WFTV
Lou Reese Net WorthInsider Trades and Bio as of Apr 21, 2026 - Benzinga
Vaxxinity is brewing up meds for a spacefaring future - Pharma Voice
Vaxxinity, UCF to develop special new vaccines for deep-space astronauts - The Business Journals
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference - GlobeNewswire
Vaxxinity making vaccines to change the world - Labiotech.eu
Vaxxinity, Inc. (VAXX) stock price, news, quote and history - Yahoo Finance Singapore
Private companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap decline - Yahoo Finance
Vaxxinity to Present at Upcoming Investor Conferences in September - GlobeNewswire
Vaxxinity publishes positive results in Alzheimer’s trial - Longevity.Technology
Innovative Alzheimer's Disease Vaccine Candidate Can Add Value - Walgreens
Vaxxinity Says UB-311 Shows Potential Advancements in Alzheimer’s Treatment - Yahoo Finance
Vaxxinity | 10-Q: Q2 2023 Earnings Report - Moomoo
Vaxxinity Company Profile & Introduction - Moomoo
Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director - GlobeNewswire
Parkinson’s Patients Treatment Posts Positive Engagement - Walgreens
Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients - Yahoo Finance
Michael J. Fox Foundation Funds Parkinson’s Disease Vaccine Candidate - Walgreens
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease - Florida Hospital News and Healthcare Report
Vaxxinity celebrates trial success in early Parkinson’s therapy - Clinical Trials Arena
Positive Phase 1 Results: Vaxxinity’s UB-312 Shows Promise in Parkinson’s Disease - Yahoo Finance
Vaxxinity shares update about potential vaccine UB-312 - Parkinson's News Today
Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewswire
Vaxxinity, Inc. (VAXX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
0.52%
자본화:
|
볼륨(24시간):